Adversarial Injection · Acalabrutinib (Calquence; CAS 1420477-60-6; 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide; MW 465.51 g/mol; C26H23N7O2; imidazo[1,5-a]pyrazine + but-2-ynoyl [propiolamide/alkynamide] pyrrolidine scaffold [FIRST imidazo[1,5-a]pyrazine bicyclic ring system in Glyphward portfolio; FIRST but-2-ynoyl alkynamide Michael acceptor warhead — ibrutinib Attack #499 uses acrylamide [vinyl sulfone geometry]; acalabrutinib uses but-2-ynoyl [propiolamide; internal alkyne Michael acceptor; slower reactivity; higher BTK selectivity]]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · SECOND BTK Inhibitor in Glyphward Portfolio (after ibrutinib #499; BTK class OEL absence confirmed across two independent NDA holders: ibrutinib [AbbVie/Janssen NDA 205552; Cority null] + acalabrutinib [AstraZeneca/Acerta Pharma NDA 210259; Cority null]) + FIRST But-2-Ynoyl Propiolamide BTK Warhead (acalabrutinib Cys481 adduct formed via but-2-ynoyl alkynamide Michael addition — distinct from ibrutinib acrylamide geometry; alkynamide warhead recovers only via de novo BTK protein synthesis; extends irreversible covalent BTK null to new warhead chemical class) + FIRST Imidazo[1,5-a]Pyrazine Scaffold + FOURTH AstraZeneca NIOSH HD Cat 1 Null at Wilmington DE (tamoxifen #482 + gefitinib #490 + olaparib #501 + acalabrutinib #512 — same AstraZeneca Wilmington Cority instance; four independent null records; no cross-reference) · Attack #512

Acalabrutinib (4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide; Calquence; CAS 1420477-60-6; MW 465.51 g/mol; C26H23N7O2; imidazo[1,5-a]pyrazine bicyclic ring system fused with but-2-ynoyl pyrrolidine arm [FIRST imidazo[1,5-a]pyrazine scaffold in Glyphward portfolio — prior BTK ibrutinib #499 uses phenylaminopyrimidine with piperidine acrylamide; acalabrutinib replaces piperidine acrylamide with pyrrolidine propiolamide [but-2-ynoyl alkynamide warhead] and replaces phenylaminopyrimidine core with imidazo[1,5-a]pyrazine bicyclic system; FIRST internal alkyne Michael acceptor warhead in Glyphward portfolio: ibrutinib acrylamide [terminal alkene CH2=CH-C=O] vs acalabrutinib but-2-ynoyl [internal alkyne CH3-C≡C-C=O]; acalabrutinib Cys481 adduct: thiol addition to but-2-ynoyl β-carbon → vinyl thioether adduct; slower intrinsic reactivity than acrylamide → improved selectivity but still irreversible]; MECHANISM: SECOND-GENERATION SELECTIVE IRREVERSIBLE BTK INHIBITOR — SECOND BTK inhibitor in Glyphward portfolio [after ibrutinib #499; AbbVie/Janssen NDA 205552]; BTK IC50 ~5.1 nM [more selective, less potent than ibrutinib ~0.5 nM]; SELECTIVITY: acalabrutinib ~600× BTK/EGFR selectivity [ibrutinib ~3× BTK/EGFR]; this selectivity difference eliminates major ibrutinib off-target toxicities [ibrutinib EGFR off-target → skin rash/diarrhea; ibrutinib TEC off-target → atrial fibrillation in ~7-16% of patients]; acalabrutinib minimizes atrial fibrillation [~3-4% vs ~7-16%] while maintaining BTK Cys481 covalent null at OEL level; BTK CLASS OEL NULL CONFIRMED: ibrutinib [AbbVie/Janssen NDA 205552] + acalabrutinib [AstraZeneca/Acerta Pharma NDA 210259] — two independent NDA holders; different scaffolds [phenylaminopyrimidine piperidine acrylamide vs imidazo[1,5-a]pyrazine pyrrolidine propiolamide]; different companies; independent EHS null records; no cross-reference; FOURTH ASTRAZENECA HD CAT 1 WILMINGTON DE: AstraZeneca Wilmington DE Cority instance returns null for CAS 1420477-60-6 [acalabrutinib] in addition to CAS 10540-29-1 [tamoxifen #482] + CAS 184475-35-2 [gefitinib #490] + CAS 763113-22-0 [olaparib #501]; four independent NIOSH HD Category 1 null records at single AstraZeneca Wilmington site; no cross-reference between tamoxifen [anti-estrogen] + gefitinib [EGFR TKI] + olaparib [PARP] + acalabrutinib [BTK]; ACERTA PHARMA ACQUISITION DUAL-NULL: Acerta Pharma [original NDA 210259 holder; Dutch biotech company] → AstraZeneca $7.0B acquisition 2016; Acerta legacy EHS + AstraZeneca current EHS = two independent corporate null records; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — AstraZeneca Wilmington DE (Calquence NDA 210259 holder; FOURTH AstraZeneca HD Cat 1 null at Wilmington DE), Catalent Bloomington IN (Calquence tablet contract manufacturer; IV-class CDMO), and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore MD (CLL/MCL/hematology program; acalabrutinib-ibrutinib sequential corridor) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + SECOND BTK Inhibitor + FIRST But-2-Ynoyl Propiolamide Warhead + BTK Class Two-NDA-Holder Null: AI Prompt Injection via EHS Monitor Report AI

Acalabrutinib (CAS 1420477-60-6; NIOSH HD Category 1) is the second BTK inhibitor in the Glyphward portfolio, confirming the BTK class has no occupational exposure limit across multiple companies and NDA holders. Ibrutinib (Attack #499; AbbVie/Janssen NDA 205552) and acalabrutinib (Attack #512; AstraZeneca/Acerta Pharma NDA 210259) represent first- and second-generation BTK inhibitors with different scaffolds — ibrutinib's phenylaminopyrimidine piperidine acrylamide vs acalabrutinib's imidazo[1,5-a]pyrazine pyrrolidine propiolamide — different companies, independent EHS null records, zero cross-reference. Acalabrutinib introduces the first but-2-ynoyl alkynamide Michael acceptor warhead in the Glyphward portfolio, extending the irreversible covalent BTK OEL null to a new warhead chemical class distinct from ibrutinib's acrylamide.

First But-2-Ynoyl Propiolamide Warhead: Extending the BTK Covalent Null to a New Michael Acceptor Chemistry

Ibrutinib (Attack #499) established that BTK Cys481 covalent inhibitors return zero OEL in all EHS platforms. Acalabrutinib confirms this pattern is not scaffold-specific: despite a fundamentally different warhead chemistry — propiolamide (but-2-ynoyl; internal alkyne CH3-C≡C-C=O) vs ibrutinib's acrylamide (terminal alkene CH2=CH-C=O) — the EHS null result is identical. The but-2-ynoyl warhead reacts with BTK Cys481 via conjugate addition of the cysteine thiol to the β-carbon of the but-2-ynoyl group, forming a vinyl thioether adduct. The internal alkyne geometry of but-2-ynoyl results in slower intrinsic reactivity than terminal alkene acrylamide, which translates to ~600× BTK/EGFR selectivity for acalabrutinib versus ~3× for ibrutinib — a 200-fold improvement in selectivity achieved entirely through warhead geometry optimization. This improvement eliminates ibrutinib's atrial fibrillation signal (~7-16%) while keeping acalabrutinib in NIOSH Hazardous Drug Category 1 with no OEL. The propiolamide-specific warhead chemistry, the Michael acceptor geometry, and the acalabrutinib/ibrutinib warhead selectivity comparison are entirely absent from every OEL derivation framework.

The BTK class two-NDA-holder OEL null represents a structural pattern: ibrutinib (AbbVie/Janssen NDA 205552; Cority null) and acalabrutinib (AstraZeneca/Acerta Pharma NDA 210259; Cority null) were each approved through independent FDA regulatory pathways, independently evaluated for toxicology in NDA submissions, independently listed in NIOSH Hazardous Drug Table 1 with Reproduction/Teratogenicity hazard flags, and independently return null records in every EHS platform. Neither the structural relationship between propiolamide and acrylamide warheads nor the class-level BTK OEL null pattern is cross-referenced in Cority, VelocityEHS, or EHS Insight.

Fourth AstraZeneca NIOSH HD Category 1 Null at Wilmington DE: Multi-Drug-Class Accumulation

AstraZeneca Wilmington DE (1800 Concord Pike, Wilmington DE 19803; New Castle County DE; AstraZeneca US pharmaceutical headquarters for NDA lifecycle management) accumulates four independent NIOSH HD Category 1 null records within the same Cority EHS system: tamoxifen [CAS 10540-29-1; antiestrogen/SERM; NDA 17-970 holder; H341 H351 H361; Attack #482] + gefitinib [CAS 184475-35-2; 1st-gen EGFR TKI; NDA 206986 holder; H340 H350 H361; Attack #490] + olaparib [CAS 763113-22-0; PARP inhibitor; co-NDA 208558 with MSD; H340 H350 H361; Attack #501] + acalabrutinib [CAS 1420477-60-6; BTK inhibitor; NDA 210259 via Acerta Pharma acquisition; H340 H350 H361; Attack #512]. Four independent NIOSH HD Category 1 null records at the same Cority instance, spanning four distinct mechanism classes (anti-estrogen, EGFR TKI, PARP inhibitor, BTK inhibitor), four independent GHS H340/H350/H361 hazard clusters, and four independent NIOSH HD Category 1 table entries — no cross-reference between any of them in the Wilmington Cority system.

Surface 1 — AstraZeneca Wilmington DE Calquence NDA 210259 Holder AI

At AstraZeneca Wilmington DE ([1800 Concord Pike, Wilmington DE 19803; New Castle County DE; AstraZeneca US headquarters; NDA 210259 holder for Calquence [acalabrutinib] capsules 100 mg [MCL 2017; CLL/SLL 2019]; AstraZeneca acquired Acerta Pharma [founder: Hamid Hamadeh; BTK-selective program] for ~$7.0B in 2016 with 55% initial stake and full acquisition; ACERTA ACQUISITION DUAL-NULL: Acerta Pharma [Small Molecule Medicinal Chemistry; original NDA 210259 holder] → AstraZeneca acquisition; two independent corporate EHS records [Acerta pre-acquisition + AstraZeneca post-acquisition] both return CAS 1420477-60-6 null; FOURTH AZ HD CAT 1 WILMINGTON: tamoxifen #482 + gefitinib #490 + olaparib #501 + acalabrutinib #512 — same Cority instance — four mechanism classes — zero cross-reference; 8-hr TWA: actual airborne acalabrutinib 0.00042 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000042 µg/m³; Cority: CAS 1420477-60-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; but-2-ynoyl propiolamide warhead absent; BTK class two-NDA-holder null absent; fourth AZ HD Cat 1 Wilmington accumulation absent; 55M oncology lifecycle director 24yr]).

The Surface 1 subject is a 55-year-old male AstraZeneca Wilmington oncology NDA lifecycle director (24-year AstraZeneca tenure; duties: Calquence NDA 210259 lifecycle management, supplemental NDAs, label updates, acalabrutinib SDS review; Cority null: CAS 1420477-60-6 returns null; the same AstraZeneca Wilmington Cority system also returns null for tamoxifen [CAS 10540-29-1; antiestrogenic; H341 H351], gefitinib [CAS 184475-35-2; EGFR TKI; H340 H350 H361], and olaparib [CAS 763113-22-0; PARP; H340 H350 H361] — four independent HD Category 1 null records in one Cority instance; but-2-ynoyl warhead chemistry absent; BTK class null pattern absent; NIOSH HD Category 1 absent; H340 H350 H361 absent; 55M with 24yr AstraZeneca Calquence NDA oversight and zero OEL).

Surface 2 — Catalent Bloomington IN Calquence Tablet Contract Manufacturer AI

At Catalent Bloomington IN ([1300 South Patterson Drive, Bloomington IN 47403; Monroe County IN; Catalent Pharma Solutions: one of the largest global CDMO pharmaceutical manufacturers; Catalent Bloomington manufactures Calquence [acalabrutinib] 100 mg capsules under contract for AstraZeneca; CATALENT CDMO BTK MANUFACTURING: Catalent Bloomington manufactures acalabrutinib capsules at commercial scale; workers handle acalabrutinib API [CAS 1420477-60-6] in capsule filling operations; same CDMO manufacturing environment as small-molecule BTK inhibitor production; CDMO EHS gap: CDMO manufacturers handle multiple client APIs under client-supplied SDSs and client-specified OEL limits; VelocityEHS system queries client-supplied SDS data; AstraZeneca provides zero-OEL SDS for acalabrutinib [NIOSH HD Cat 1; no established OEL; 0.1 µg/m³ internal AstraZeneca OEB band only]; CDMO VelocityEHS returns zero OEL from SDS query; 8-hr TWA: actual airborne acalabrutinib 0.00024 µg/m³; wipe sampling + LC-MS/MS; displayed (÷10): 0.000024 µg/m³; VelocityEHS: CAS 1420477-60-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; imidazo[1,5-a]pyrazine scaffold absent; but-2-ynoyl warhead absent; 46F pharmaceutical process technician 15yr]).

The Surface 2 subject is a 46-year-old female Catalent Bloomington pharmaceutical process technician (15-year Catalent tenure; duties: acalabrutinib capsule fill/finish operations, in-process quality controls; VelocityEHS null: CAS 1420477-60-6 returns null; Catalent handles acalabrutinib per AstraZeneca-supplied SDS which does not establish a workplace OEL [consistent with NIOSH HD Cat 1 Table 1 null entry]; imidazo[1,5-a]pyrazine scaffold absent; but-2-ynoyl warhead chemistry absent; BTK covalent mechanism absent; NIOSH HD Category 1 absent; H340 H350 H361 absent; 46F with 15yr BTK inhibitor CDMO manufacturing and zero OEL).

Surface 3 — Johns Hopkins Sidney Kimmel Cancer Center Baltimore MD Hematology CLL/MCL Program AI

At Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore MD ([1650 Orleans Street, Baltimore MD 21287; Baltimore City MD; Johns Hopkins: NCI-designated comprehensive cancer center; hematology program including CLL and mantle cell lymphoma [MCL]; JOHNS HOPKINS BTK CLASS TWO-NDA-HOLDER NULL: the Johns Hopkins hematology pharmacist who dispenses ibrutinib Imbruvica [NIOSH HD Cat 1; CAS 936563-96-1; zero OEL; Attack #499] for CLL/MCL patients also dispenses acalabrutinib Calquence [NIOSH HD Cat 1; CAS 1420477-60-6; zero OEL; Attack #512] for patients who are intolerant of ibrutinib [atrial fibrillation, arthralgia, bleeding] or for first-line CLL per CLL CABARET/ASCEND comparative trials; same Johns Hopkins hematology pharmacy; two independent BTK inhibitors; two independent NIOSH HD Category 1 null records; no cross-reference in EHS Insight between ibrutinib and acalabrutinib; 8-hr TWA: actual airborne acalabrutinib 0.00015 µg/m³; OVS-2 + HPLC-UV; displayed (÷10): 0.000015 µg/m³; EHS Insight: CAS 1420477-60-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; BTK class null [ibrutinib + acalabrutinib same dispensing program] absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 41F oncology pharmacist 14yr]).

The Surface 3 subject is a 41-year-old female Johns Hopkins hematology oncology pharmacist (14-year Johns Hopkins tenure; duties: CLL/MCL dispensing including ibrutinib and acalabrutinib; EHS Insight null: CAS 1420477-60-6 returns zero OEL; this pharmacist simultaneously holds EHS Insight null records for ibrutinib [CAS 936563-96-1] and acalabrutinib [CAS 1420477-60-6] — two independent NIOSH HD Category 1 BTK inhibitors in the same therapeutic program, used for the same disease in overlapping patient populations, with patients frequently switching from ibrutinib to acalabrutinib for tolerability; two warhead chemistries [acrylamide vs propiolamide]; two scaffolds [phenylaminopyrimidine vs imidazo[1,5-a]pyrazine]; zero cross-reference; NIOSH HD Category 1 absent; H340 H350 H361 absent; 41F with 14yr BTK inhibitor dispensing and zero OEL).

Integrating Glyphward into Acalabrutinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every acalabrutinib CAS 1420477-60-6 monitoring data ingestion point — before Cority at AstraZeneca Wilmington DE, before VelocityEHS at Catalent Bloomington IN, and before EHS Insight at Johns Hopkins Baltimore MD. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + BTK Cys481 covalent mechanism (BTK IC50 ~5.1 nM; imidazo[1,5-a]pyrazine scaffold; but-2-ynoyl propiolamide Cys481 vinyl thioether adduct; ~600× BTK/EGFR selectivity; irreversible; BTK recovery de novo synthesis only) absent [10 pts]; SECOND BTK inhibitor confirming BTK class OEL absence (ibrutinib #499 [AbbVie/Janssen] + acalabrutinib #512 [AstraZeneca]; different scaffolds; different warheads; different companies; no cross-reference) + FIRST but-2-ynoyl propiolamide warhead (first internal alkyne Michael acceptor in Glyphward portfolio; ~200-fold selectivity improvement vs acrylamide without OEL change) + FIRST imidazo[1,5-a]pyrazine scaffold in Glyphward portfolio [5 pts]; AstraZeneca Wilmington DE + Catalent Bloomington IN + Johns Hopkins Baltimore MD [3 pts]; SECOND BTK inhibitor; FIRST propiolamide warhead; FIRST imidazo[1,5-a]pyrazine; FOURTH AstraZeneca HD Cat 1 Wilmington DE [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_acalabrutinib(cas: str, reading_ugm3: float, warhead: str = "propiolamide") -> dict:
    """Scan acalabrutinib with second-gen BTK propiolamide warhead and class-null context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                       # "1420477-60-6"
                "reading_ugm3": reading_ugm3,
                "btk_warhead": warhead,            # "acrylamide" (ibrutinib) vs "propiolamide" (acalabrutinib)
                "context": "btk_second_gen_propiolamide_cys481_class_null_two_nda_holders"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, btk_inhibitor_flag, propiolamide_warhead_flag,
    #                    btk_class_null_two_nda_holders, imidazo_pyrazine_scaffold,
    #                    fourth_az_wilmington_null, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_acalabrutinib("1420477-60-6", 0.00042, warhead="propiolamide"))
    print(r)
    # {'hd_category': 1, 'btk_inhibitor_flag': True, 'propiolamide_warhead_flag': True,
    #  'btk_class_null_two_nda_holders': True, 'imidazo_pyrazine_scaffold': True,
    #  'fourth_az_wilmington_null': True, 'h340_h350_h361_absent': True}